Browse by author
Lookup NU author(s): Dr Harish Datta
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
In elderly women, loss in bone mass and micro-architectural changes are generally attributed to the onset of menopause. Men do not experience menopause, they do, however, experience age-related acceleration in bone loss and micro-architecture deterioration. The incidence of osteoporotic fractures in elderly men, just as in aged women, increases exponentially with age; the rise in men, however, is some 5-10 years later than in women. Up to 50% of male osteoporotics have no identifiable etiology; however elderly males have much higher likelihood of having an identifiable secondary cause than younger men. Therefore, clinical and laboratory evaluation of aged male osteoporotics must be thorough and should be aimed at identifying lifestyle or conditions contributing to bone loss and fragility. It is essential to identify and treat secondary causes and ensure adequate vitamin D and calcium intake before embarking upon treatment with pharmacological agents. The evidence from a limited number of trials suggests that bisphosphonates, especially alendronate and risedronate, are effective in improving BMD, and seem to be the treatments of choice in aged men with osteoporosis. In cases where bisphosphonates are contra-indicated or ineffective, teriparatide or alternatives such as strontium should be considered.
Author(s): Tuck SP, Datta HK
Publication type: Review
Publication status: Published
Journal: Clinical Interventions in Aging
Year: 2007
Volume: 2
Issue: 4
Pages: 521-536
ISSN (print): 1176-9092
ISSN (electronic): 1178-1998
Publisher: DOVE MEDICAL PRESS LTD
URL: http://dx.doi.org/10.2147/CIA.S820
DOI: 10.2147/CIA.S820
